Gelfand described psoriasis as an inflammatory metabolic disease. Among inflammatory diseases of medicine, he said psoriasis has by far the closest association with obesity. Obesity makes psoriasis ...

Fed up with flakes on your shoulders and an itchy scalp that just won't settle? Before you buy yet another shampoo, here's ...

Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

Alumis' Phase 3 ONWARD data show envudeucitinib delivers durable scalp clearance and itch relief through 48 weeks in ...

A national analysis of US ambulatory care visits finds patients with psoriasis have more than eightfold increased odds of ...

While TB and meningitis are rare among patients receiving systemic psoriasis therapies, IL-17 inhibitors increase the risk for candidiasis.

A two-year Japanese real-world study of 66 patients shows the dual IL-17A and IL-17F inhibitor bimekizumab sustained high ...

Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth ...

Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.

New data from an Eli Lilly study found that adults with moderate-to-severe psoriasis and obesity experienced broader immune ...

Combining Taltz and Zepbound improves psoriasis symptoms and metabolic biomarkers in patients with obesity.